
Opinion|Videos|August 14, 2024
Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.
Advertisement
Episodes in this series

This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following questions:
- What are some of the most common concerns or questions newly diagnosed CML patients may have about their initial treatment plan?
- What are some common adverse effects or tolerability challenges patients may experience with their initial treatment plan?
- What is your best practice to set clear expectations with your patients on what they may experience along their CML journey?
Advertisement
Related to this article

Oncology nurse April Fowler shares her personal stage 4 cancer journey, reflecting on clinical empathy, patient advocacy, and oncology endurance.

Dr. Jason Konner discusses psilocybin, clinician burnout, CIPN prevention, and safety protocols for oncology nurses and care teams in cancer care.

FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.

ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.

From ICN 2026, Heather Jackson and Ashley Johnson detail APP breast care access models, global cancer pain barriers, and burnout mitigation tactics.

FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Reframing Nurse Fatigue as Systemic Safety Risk
2
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
3
Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care
4
FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell RCC
5


